Aptamers Engineered Nanocarriers for Cancer Therapy
- 1st Edition - September 25, 2022
- Latest edition
- Editor: Prashant Kesharwani
- Language: English
Aptamers Engineered Nanocarriers for Cancer Therapy details the selection technologies, biological characteristics, and clinical uses of aptamer-based nano agents for cancer th… Read more
Description
Description
Aptamers Engineered Nanocarriers for Cancer Therapy details the selection technologies, biological characteristics, and clinical uses of aptamer-based nano agents for cancer therapeutics. The book helps facilitate speedy solutions for some of the problems pertaining to the manufacture of nano-aptamers – such as toxicity, thermal stability, cost efficiency, tumor penetration and blood stability. Key chapters cover cell-SELEX technology for aptamer selection, mechanisms of multi-drug resistance of cancer, the relevance of aptamers as anticancer therapies, as well as the broad range of aptamer-functionalized nanostructures available.
This book provides exciting insights into this relatively new approach to cancer therapeutics, and will be of interest to materials scientists, biomedical engineers, molecular biologists, biochemists and clinical scientists, with a focus on cancer therapy.
Key features
Key features
- Reviews the mechanisms behind multi-drug resistance (MDR) in cancer and how aptamer-mediated novel therapeutic agents and strategies can facilitate MDR reversal
- Covers a range of aptamers engineered nanostructures, including PLGA nanoparticles, silica nanoparticles, quantum dots, nucleic acid aptamers, and more
- Discusses the challenges associated with using aptamers as cancer therapeutics and how this translates into clinical use
Readership
Readership
Table of contents
Table of contents
2. Biological characteristics of aptamers
3. Mechanisms of multi-drug resistance of cancer
4. Relevance of aptamers as targeting ligands for anticancer therapies
5. Aptamers as smart ligands for nano-carriers cancer targeting
6. Aptamer-functionalized liposomes for targeted cancer therapy
7. Aptamer-functionalized micelles for targeted cancer therapy
8. Aptamer-functionalized nanoparticles for targeted cancer therapy
9. Aptamer-functionalized PLGA nanoparticles for targeted cancer therapy
10. Aptamer-functionalized silica nanoparticles for targeted cancer therapy
11. Aptamer-functionalized gold nanoparticles for targeted cancer therapy
12. Aptamer-functionalized dendrimers for targeted cancer therapy
13. Aptamer-functionalized carbon nanotubes for targeted cancer therapy
14. Aptamer-functionalized quantum dots for targeted cancer therapy
15. Cancer immunotherapy via nucleic acid aptamers
16. Aptamer-based imaging and diagnostics for cancer cells
17. Microdevice-based aptamer sensors
18. Aptamer-based microfluidics for circulating tumor cells
19. Aptamer-based theranostic approaches for treatment of cancer
20. Challenges of aptamers as targeting ligands for anticancer therapies
21. Clinical use and future perspective of aptamers
Product details
Product details
- Edition: 1
- Latest edition
- Published: September 28, 2022
- Language: English
About the editor
About the editor
PK
Prashant Kesharwani
Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya University, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience across various countries. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, and “SERB-Ramanujan Fellowship Award”. He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.